Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing challenges in the biotech funding environment, which dampened demand from smaller clients, and the loss of a major commercial customer in the Manufacturing segment. CEO James Foster explained that “client demand has stabilized,” but acknowledged lingering end market uncertainty, particularly among mid-sized biotech customers who remain cautious amid funding constraints.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 7.5% gain for healthcare stocks has fallen short of the S&P 500’s 15.3% rise.
Recent third-quarter (Q3) 2025 corporate earnings have painted a complex yet largely positive picture for North American equity markets. While robust performances from key sectors, particularly technology, have propelled major U.S. and Canadian indices to new heights, a closer look reveals a landscape of mixed results, with individual company
Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses.
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.
Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share was 3.9% above analysts’ consensus estimates.
Lab services company Charles River Laboratories (NYSE:CRL)
will be announcing earnings results this Wednesday before market hours. Here’s what you need to know.
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Charles River Laboratories (NYSE:CRL) and its peers.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 2.6% in the afternoon session after the stock's positive momentum continued, as Barclays upgraded the company to Overweight from Equal Weight and raised its price target.
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 1.9% in the morning session after Barclays upgraded the company to Overweight from Equal-Weight and raised its price target.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
